260 related articles for article (PubMed ID: 33389440)
1. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
Devi A; Chaitanya NSN
Mol Divers; 2022 Feb; 26(1):157-169. PubMed ID: 33389440
[TBL] [Abstract][Full Text] [Related]
2. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10266-10272. PubMed ID: 33561300
[TBL] [Abstract][Full Text] [Related]
3. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
4. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
5. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*.
Schmitz A; Weber A; Bayin M; Breuers S; Fieberg V; Famulok M; Mayer G
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10279-10285. PubMed ID: 33683787
[TBL] [Abstract][Full Text] [Related]
6. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
7.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
8. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry.
Valero J; Civit L; Dupont DM; Selnihhin D; Reinert LS; Idorn M; Israels BA; Bednarz AM; Bus C; Asbach B; Peterhoff D; Pedersen FS; Birkedal V; Wagner R; Paludan SR; Kjems J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876524
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Efficacy of Selected Natural Phytochemicals against SARS-CoV-2 Spike Glycoprotein Using Structure-Based Drug Designing.
Aloufi BH; Snoussi M; Sulieman AME
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458599
[TBL] [Abstract][Full Text] [Related]
10. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
12. In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.
Lin YC; Chen WY; Hwu ET; Hu WP
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628622
[TBL] [Abstract][Full Text] [Related]
13. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism of Interaction between DNA Aptamer and Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Revealed by Steered Molecular Dynamics Simulations.
Ding X; Xu C; Zheng B; Yu H; Zheng P
Molecules; 2024 May; 29(10):. PubMed ID: 38792076
[TBL] [Abstract][Full Text] [Related]
15. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
17. Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19.
Gurung AB; Ali MA; Lee J; El-Zaidy M; Aljowaie RM; Almutairi SM
PLoS One; 2022; 17(6):e0268919. PubMed ID: 35657783
[TBL] [Abstract][Full Text] [Related]
18. In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2.
Geromichalou EG; Geromichalos GD
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364398
[TBL] [Abstract][Full Text] [Related]
19. Computational Design of 25-mer Peptide Binders of SARS-CoV-2.
Sitthiyotha T; Chunsrivirot S
J Phys Chem B; 2020 Dec; 124(48):10930-10942. PubMed ID: 33200935
[TBL] [Abstract][Full Text] [Related]
20.
Chen Y; Yang X; Liu J; Zhang D; He J; Tang L; Li J; Xiang Q
Nucleosides Nucleotides Nucleic Acids; 2023; 42(2):105-118. PubMed ID: 35949145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]